Pathogen reduction technologies for blood products: a review of the clinical effectiveness, cost-effectiveness, and guidelines

Mujoomdar M, Clark M,Cunningham J
Record ID 32011001234
English
Authors' recommendations: Overall, the available evidence indicates that the INTERCEPT Blood System photochemical process (amotosalen + UVA light) does not adversely affect the clinical utility of the treated blood components, specifically plasma and platelet components. INTERCEPT-treated components were able to improve hemostasis in all of the included studies and had a comparable AE profile to conventionally-prepared plasma and platelet components.One study examined the incidence of antibody development to potential neoantigens on Mirasol-treated platelets in blood product recipients. The authors concluded that neoantigen formation is not a potential side effect of photochemical treatment of platelets. Three cost utility analyses and one cost-effectiveness study concluded that pathogen reduction technologies are cost-effective. No information regarding these latter two outcomes was identified for inclusion by the literature search. In addition, no guidelines about the use of PRT were identified.
Details
Project Status: Completed
URL for project: http://www.cadth.ca/media/pdf/L0134_Pathogen_Reduction_Technologies_final.pdf
Year Published: 2009
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Canada
MeSH Terms
  • Blood Platelets
  • Blood Preservation
  • Blood Transfusion
  • Cell Proliferation
  • Disinfection
  • Leukocyte Reduction Procedures
Contact
Organisation Name: Canadian Agency for Drugs and Technologies in Health
Contact Address: 600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553; Fax: +1 613 226 5392;
Contact Name: requests@cadth.ca
Contact Email: requests@cadth.ca
Copyright: Canadian Agency for Drugs and Technologies in Health (CADTH)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.